Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

2
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
2
Myocarditis II: Clinical features and Diagnostic Tests01:27

Myocarditis II: Clinical features and Diagnostic Tests

2
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
2
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
118

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Onycho-oncology: A Useful Neologism.

Journal of the American Academy of Dermatology·2026
Same author

Mitigating the Increasing Squamous Cell Carcinoma Burden.

Journal of the American Academy of Dermatology·2026
Same author

The wide world of glucagon-like peptide-1 agonist therapy: The thrill of weight loss and the agony of alopecia.

Journal of the American Academy of Dermatology·2026
Same author

Spironolactone rules.

Journal of the American Academy of Dermatology·2026
Same author

Visual recognition and medical dermatology learning needs identified through continuing certification program assessments of the American Board of Dermatology.

Journal of the American Academy of Dermatology·2026
Same author

Mitigating dermatologic malpractice risk: Dueling the sword of Damocles.

Journal of the American Academy of Dermatology·2026
Same journal

Dermatologic conditions associated with HIV among US adults across different racial and ethnic groups: A retrospective cohort study using TriNetX.

Journal of the American Academy of Dermatology·2026
Same journal

Ethical Considerations in Same-Day Surgical Treatment of a High-Risk, Poorly Differentiated Squamous Cell Carcinoma.

Journal of the American Academy of Dermatology·2026
Same journal

The Ethics of the Handshake in Dermatology.

Journal of the American Academy of Dermatology·2026
Same journal

Dermatology images: Hidradenitis suppurativa.

Journal of the American Academy of Dermatology·2026
Same journal

Response to Guo et al., "Response to Huang et al.'s 'Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: an analysis of national multicenter data from the CRDC.'".

Journal of the American Academy of Dermatology·2026
Same journal

Genomic Predictors of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Insights from an MD Anderson Cohort.

Journal of the American Academy of Dermatology·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2025

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.5K

Refining dermatomyositis

Warren R Heymann1

  • 1Marlton, New Jersey.

Journal of the American Academy of Dermatology
|October 11, 2024
PubMed
Summary

No abstract available in PubMed .

Keywords:
dermatomyositisinterstitial lung diseasemyositis-specific antibodies

More Related Videos

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.1K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K

Related Experiment Videos

Last Updated: Jun 10, 2025

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.5K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.1K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K